© 2022 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#dialysis

The Liver Meeting 2018 Roundup

A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco

Mavyret Is Safe for Those With Severely Impaired Kidneys

A recent analysis of two studies of AbbVie’s hepatitis C regimen showed good results in this population.

For Those on Dialysis, Epclusa Is an Option for Hepatitis C Treatment

In a recent study of Gilead’s Epclusa (sofosbuvir/velpatasvir), 92 percent of participants were on dialysis and 29 percent had cirrhosis.

Transplanting Hep–Positive Kidneys Is Cost-Effective

Researchers crunched the numbers for transplanting kidneys from donors with hep C and then treating the virus in the recipient.

Treating Hepatitis C Among Those on Dialysis Lowers Risk of Death

This is according to a large study of Swedish people with hep C and chronic kidney disease.

How Does Hepatitis C Affect Non-Liver-Related Health?

And can treating the virus reduce the risk of chronic kidney and cardiovascular diseases as well as the risk of death from such causes?
Advertisement

Hep uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. Our Privacy Policy

Manage

Hep uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. By remaining on our website, you indicate your consent to our Privacy Policy and our Cookie Usage.